| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 56.37 | 99.0% |
| Total Income | 56.37 | 99.0% |
| Expenditure | 60.02 | 26.0% |
| PBT | 2.28 | 119.5% |
| Net Profit | 3.78 | 132.4% |
| OPM | -6.47% | 61.71pp |
| NPM | 6.71% | 47.86pp |
| EPS | 0.06 | 131.6% |
Protagonist Reports Q1 2026 Financial Results; License and collaboration revenue $56.4M
06 May 2026 · 6 May, 1:44 am
Summary
Protagonist Therapeutics reported its financial results for the first quarter ended March 31, 2026. The company's license and collaboration revenue was $56.4 million, which included a $50.0 million milestone from the FDA approval of ICOTYDE. Net income for the quarter was $3.8 million, or $0.06 per basic share. As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $620.3 million. Protagonist exercised its rusfertide opt-out right, triggering a $200 million payment.
Key Highlights
- 1
Protagonist Therapeutics reported license and collaboration revenue of $56.4 million for the first quarter ended March 31, 2026.
- 2
The FDA approval of ICOTYDE triggered a $50.0 million milestone payment to Protagonist in Q1 2026.
- 3
Net income for the first quarter of 2026 was $3.8 million, or $0.06 per basic share.
- 4
Cash, cash equivalents, and marketable securities totaled $620.3 million as of March 31, 2026.
- 5
Protagonist exercised its rusfertide opt-out right, triggering a $200 million payment.
- 6
The FDA accepted the New Drug Application for rusfertide and granted Priority Review with a PDUFA goal date in August 2026.
Management Comments
Dinesh V. Patel
Ph.D.
“The first quarter of 2026 marked a series of landmark achievements for Protagonist, highlighted by the U.S. approval of ICOTYDE, FDA granting Priority Review for rusfertide, and advancement of our highly differentiated and fully-owned peptides PN-881 and PN-477. These accomplishments, together with the additional financial resources afforded by our rusfertide opt-out election and future milestones and royalty payments from ICOTYDE and rusfertide, position Protagonist for meaningful near-, medium and long-term value creation through rapid progression of clinical stage assets and further expansion into new internal discovery programs. In addition, we look forward to implementing an efficient capital return strategy at the appropriate time.”
Informational and educational content only. Not investment advice.